• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然植物治疗非酒精性脂肪性肝病的潜力:针对肠道微生物群和胆汁酸的相互作用。

Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.

机构信息

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, China.

出版信息

Front Cell Infect Microbiol. 2022 Mar 9;12:854879. doi: 10.3389/fcimb.2022.854879. eCollection 2022.

DOI:10.3389/fcimb.2022.854879
PMID:35356532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8959594/
Abstract

Non-alcoholic fatty liver disease (NAFLD) remains a common disease with a significant health and economic burden worldwide. The gut microbiota (GM) and bile acids (BAs), which play important roles in the gut-liver axis, have been confirmed to jointly participate in the development of NAFLD. GM not only regulate bile acids' synthesis, transport, and reabsorption by regulating other metabolites (such as trimetlyl amine oxide, butyrate), but also regulate dehydrogenation, dehydroxylation and desulfurization of bile acids. Meanwhile, disordered bile acids influence the gut microbiota mainly through promoting the bacterial death and lowering the microbial diversity. Although weight loss and lifestyle changes are effective in the treatment of NAFLD, the acceptability and compliance of patients are poor. Recently, increasing natural plants and their active ingredients have been proved to alleviate NAFLD by modulating the joint action of gut microbiota and bile acids, and considered to be promising potential candidates. In this review, we discuss the efficacy of natural plants in treating NAFLD in the context of their regulation of the complex interplay between the gut microbiota and bile acids, the crosstalk of which has been shown to significantly promote the progression of NAFLD. Herein, we summarize the prior work on this topic and further suggest future research directions in the field.

摘要

非酒精性脂肪性肝病(NAFLD)仍然是一种常见疾病,在全球范围内具有显著的健康和经济负担。肠道微生物群(GM)和胆汁酸(BAs)在肠肝轴中起重要作用,已被证实共同参与 NAFLD 的发展。GM 不仅通过调节其他代谢物(如三甲胺氧化物、丁酸)来调节胆汁酸的合成、运输和重吸收,还调节胆汁酸的脱氢、去羟化和脱硫。同时,胆汁酸的紊乱主要通过促进细菌死亡和降低微生物多样性来影响肠道微生物群。虽然减肥和生活方式的改变对 NAFLD 的治疗有效,但患者的接受度和依从性较差。最近,越来越多的天然植物及其活性成分已被证明通过调节肠道微生物群和胆汁酸的共同作用来缓解 NAFLD,并被认为是有前途的潜在候选药物。在这篇综述中,我们讨论了天然植物在治疗 NAFLD 方面的功效,以及它们对肠道微生物群和胆汁酸之间复杂相互作用的调节,这些相互作用的相互作用已被证明可显著促进 NAFLD 的进展。在此,我们总结了这一领域的先前工作,并进一步提出了该领域的未来研究方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/8959594/d07389244365/fcimb-12-854879-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/8959594/0aa23afdc498/fcimb-12-854879-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/8959594/d07389244365/fcimb-12-854879-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/8959594/0aa23afdc498/fcimb-12-854879-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c9d/8959594/d07389244365/fcimb-12-854879-g002.jpg

相似文献

1
Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.天然植物治疗非酒精性脂肪性肝病的潜力:针对肠道微生物群和胆汁酸的相互作用。
Front Cell Infect Microbiol. 2022 Mar 9;12:854879. doi: 10.3389/fcimb.2022.854879. eCollection 2022.
2
Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.蒺藜草提取物通过调节肠道微生物群和胆汁酸代谢减轻小鼠非酒精性脂肪性肝病。
J Ethnopharmacol. 2022 Aug 10;294:115333. doi: 10.1016/j.jep.2022.115333. Epub 2022 Apr 29.
3
Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.肠道微生物群与非酒精性肝病的相互作用:微生物衍生代谢物的作用。
Pharmacol Res. 2019 Mar;141:521-529. doi: 10.1016/j.phrs.2019.01.029. Epub 2019 Jan 17.
4
A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.涉及肠道微生物群、循环胆汁酸和肝脏代谢基因的网络,可预防非酒精性脂肪性肝病。
Mol Nutr Food Res. 2019 Oct;63(20):e1900487. doi: 10.1002/mnfr.201900487. Epub 2019 Jul 30.
5
The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.肠道微生物群及其代谢产物:治疗和预防非酒精性脂肪性肝病的新靶点。
Mol Nutr Food Res. 2020 Sep;64(17):e2000375. doi: 10.1002/mnfr.202000375. Epub 2020 Aug 10.
6
Physical exercise plays a role in rebalancing the bile acids of enterohepatic axis in non-alcoholic fatty liver disease.体育锻炼在重新平衡非酒精性脂肪性肝病的肠肝轴胆汁酸中发挥作用。
Acta Physiol (Oxf). 2024 Jan;240(1):e14065. doi: 10.1111/apha.14065. Epub 2023 Dec 1.
7
Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.回肠胆汁酸转运蛋白抑制剂通过改善非酒精性脂肪性肝病模型小鼠肠道微生物失调改善肝脂肪变性。
mBio. 2021 Aug 31;12(4):e0115521. doi: 10.1128/mBio.01155-21. Epub 2021 Jul 6.
8
Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).肠道微生物衍生成分和代谢物在非酒精性脂肪性肝病(NAFLD)进展中的作用。
Nutrients. 2019 Jul 25;11(8):1712. doi: 10.3390/nu11081712.
9
Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.肠道微生物群与胆汁酸失调在非酒精性脂肪性肝病发病机制中的相互作用及益生菌的潜在治疗意义。
J Cell Biochem. 2019 Mar;120(3):2713-2720. doi: 10.1002/jcb.27635. Epub 2018 Nov 15.
10
Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism.肠道微生物组通过调节胆汁酸代谢来决定 OCA 对非酒精性脂肪性肝病的治疗效果。
NPJ Biofilms Microbiomes. 2023 May 31;9(1):29. doi: 10.1038/s41522-023-00399-z.

引用本文的文献

1
Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病患者血清胆汁酸谱特征
BMC Gastroenterol. 2025 May 5;25(1):334. doi: 10.1186/s12876-025-03903-1.
2
Xiaohua Funing decoction ameliorates non-alcoholic fatty liver disease by modulating the gut microbiota and bile acids.小华复宁汤通过调节肠道微生物群和胆汁酸改善非酒精性脂肪性肝病。
Front Microbiol. 2025 Feb 10;16:1511885. doi: 10.3389/fmicb.2025.1511885. eCollection 2025.
3
Plant miR6262 Modulates the Expression of Metabolic and Thermogenic Genes in Human Hepatocytes and Adipocytes.

本文引用的文献

1
Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity.咖啡因和表没食子儿茶素没食子酸酯可缓解高反式脂肪酸和高碳水化合物饮食诱导的小鼠非酒精性脂肪性肝炎:共性与特异性
Front Nutr. 2021 Nov 22;8:784354. doi: 10.3389/fnut.2021.784354. eCollection 2021.
2
Tea and its phytochemicals: Hidden health benefits & modulation of signaling cascade by phytochemicals.茶及其植物化学物质:隐藏的健康益处和植物化学物质对信号级联的调节。
Food Chem. 2022 Mar 1;371:131098. doi: 10.1016/j.foodchem.2021.131098. Epub 2021 Sep 9.
3
Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease.
植物 miR6262 调节人肝细胞和脂肪细胞中代谢和产热基因的表达。
Nutrients. 2024 Sep 18;16(18):3146. doi: 10.3390/nu16183146.
4
Toxicity assessment of Cucurbita pepo cv Dayangua and its effects on gut microbiota in mice.大冬瓜(Cucurbita pepo cv Dayangua)的毒性评估及其对小鼠肠道微生物群的影响。
BMC Complement Med Ther. 2024 Jun 22;24(1):243. doi: 10.1186/s12906-024-04551-w.
5
Plant miR8126-3p and miR8126-5p Decrease Lipid Accumulation through Modulation of Metabolic Genes in a Human Hepatocyte Model That Mimics Steatosis.植物 miR8126-3p 和 miR8126-5p 通过调节模拟脂肪变性的人肝细胞模型中的代谢基因来减少脂质积累。
Int J Mol Sci. 2024 Jan 31;25(3):1721. doi: 10.3390/ijms25031721.
6
Compound Chinese medicine (F1) improves spleen deficiency diarrhea by protecting the intestinal mucosa and regulating the intestinal flora.复方中药(F1)通过保护肠黏膜和调节肠道菌群来改善脾虚泄泻。
Front Microbiol. 2024 Jan 16;14:1292082. doi: 10.3389/fmicb.2023.1292082. eCollection 2023.
7
Male zooid extracts of ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet.雄虫提取物可改善高脂饮食诱导的小鼠非酒精性脂肪性肝病和肠道菌群失调。
Front Cell Infect Microbiol. 2022 Oct 28;12:1059647. doi: 10.3389/fcimb.2022.1059647. eCollection 2022.
疾病相关肠道微生物群减少儿科非酒精性脂肪性肝病患者次级胆汁酸谱。
Front Cell Infect Microbiol. 2021 Sep 9;11:698852. doi: 10.3389/fcimb.2021.698852. eCollection 2021.
4
Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD.胆汁酸代谢肠道微生物群和特定胆汁酸基因的改变作为一种精准医学对非酒精性脂肪性肝病进行亚分类。
Physiol Genomics. 2021 Aug 1;53(8):336-348. doi: 10.1152/physiolgenomics.00011.2021. Epub 2021 Jun 21.
5
Non-alcoholic fatty liver disease.非酒精性脂肪性肝病。
Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21.
6
Amelioration of hyperglycaemia and hyperlipidaemia by adjusting the interplay between gut microbiota and bile acid metabolism: Radix Scutellariae as a case.通过调节肠道微生物群和胆汁酸代谢之间的相互作用来改善高血糖和高血脂:以黄芩为例。
Phytomedicine. 2021 Mar;83:153477. doi: 10.1016/j.phymed.2021.153477. Epub 2021 Jan 21.
7
Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice.柑橘属植物总黄酮通过调节肠道微生物群和胆汁酸代谢减轻非酒精性脂肪性肝炎。
Biomed Pharmacother. 2021 Mar;135:111183. doi: 10.1016/j.biopha.2020.111183. Epub 2021 Jan 2.
8
The gut bacterium produces secondary bile acids and influences liver physiology in gnotobiotic mice.肠道细菌会产生次级胆汁酸,并影响无菌小鼠的肝脏生理机能。
Gut Microbes. 2021 Jan-Dec;13(1):1-21. doi: 10.1080/19490976.2020.1854008.
9
Mexican Extracts Decrease Lipogenesis Modulating Transcriptional Metabolic Networks and Gut Microbiota in C57BL/6 Mice Fed with a High-Cholesterol Diet.墨西哥提取物通过调节转录代谢网络和高脂饮食喂养的 C57BL/6 小鼠的肠道微生物群来减少脂肪生成。
Nutrients. 2020 Dec 24;13(1):38. doi: 10.3390/nu13010038.
10
Gut microbiota-derived metabolites as central regulators in metabolic disorders.肠道微生物衍生代谢物作为代谢紊乱的中心调节物。
Gut. 2021 Jun;70(6):1174-1182. doi: 10.1136/gutjnl-2020-323071. Epub 2020 Dec 3.